Sign In
Buy CTXR
$0.569
+0.0230 (+4.21%)
At Close: Jun 22, 2026
Citius Pharmaceuticals Earnings Calls
Mar 31, 2026
-$0.95 (-238.38%)
| Release date | May 15, 2026 |
| EPS estimate | -$0.281 |
| EPS actual | -$0.95 |
| EPS Surprise | -238.38% |
| Revenue estimate | 10.228M |
| Revenue actual | 1.667M |
| Revenue Surprise | -83.70% |
Dec 31, 2025
-$0.380 (-188.39%)
| Release date | Feb 13, 2026 |
| EPS estimate | $0.430 |
| EPS actual | -$0.380 |
| EPS Surprise | -188.39% |
| Revenue estimate | 18.007M |
| Revenue actual | 3.944M |
| Revenue Surprise | -78.10% |
Sep 30, 2025
-$0.441 (-83.55%)
| Release date | Dec 25, 2025 |
| EPS estimate | -$0.240 |
| EPS actual | -$0.441 |
| EPS Surprise | -83.55% |
| Revenue estimate | - |
| Revenue actual | 3.944M |
Jun 30, 2025
-$0.80 (-233.33%)
| Release date | Aug 12, 2025 |
| EPS estimate | -$0.240 |
| EPS actual | -$0.80 |
| EPS Surprise | -233.33% |
| Revenue estimate | 1.919M |
| Revenue actual | - |
Last 4 Quarters for Citius Pharmaceuticals
Below you can see how CTXR performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Jun 30, 2025
Missed
| Release date | Aug 12, 2025 |
| Price on release | $1.30 |
| EPS estimate | -$0.240 |
| EPS actual | -$0.80 |
| EPS surprise | -233.33% |
| Date | Price |
|---|---|
| Aug 06, 2025 | $1.28 |
| Aug 07, 2025 | $1.29 |
| Aug 08, 2025 | $1.23 |
| Aug 11, 2025 | $1.25 |
| Aug 12, 2025 | $1.30 |
| Aug 13, 2025 | $1.28 |
| Aug 14, 2025 | $1.31 |
| Aug 15, 2025 | $1.33 |
| Aug 18, 2025 | $1.38 |
| 4 days before | 1.56% |
| 4 days after | 6.15% |
| On release day | -1.54% |
| Change in period | 7.81% |
Sep 30, 2025
Missed
| Release date | Dec 25, 2025 |
| Price on release | $0.80 |
| EPS estimate | -$0.240 |
| EPS actual | -$0.441 |
| EPS surprise | -83.55% |
| Date | Price |
|---|---|
| Dec 18, 2025 | $1.02 |
| Dec 19, 2025 | $1.07 |
| Dec 22, 2025 | $1.05 |
| Dec 23, 2025 | $1.04 |
| Dec 24, 2025 | $0.80 |
| Dec 26, 2025 | $0.84 |
| Dec 29, 2025 | $0.83 |
| Dec 30, 2025 | $0.783 |
| Dec 31, 2025 | $0.777 |
| 4 days before | -21.51% |
| 4 days after | -2.95% |
| On release day | 5.02% |
| Change in period | -23.82% |
Dec 31, 2025
Missed
| Release date | Feb 13, 2026 |
| Price on release | $0.750 |
| EPS estimate | $0.430 |
| EPS actual | -$0.380 |
| EPS surprise | -188.39% |
| Date | Price |
|---|---|
| Feb 09, 2026 | $0.80 |
| Feb 10, 2026 | $0.81 |
| Feb 11, 2026 | $0.90 |
| Feb 12, 2026 | $0.793 |
| Feb 13, 2026 | $0.750 |
| Feb 17, 2026 | $0.742 |
| Feb 18, 2026 | $0.717 |
| Feb 19, 2026 | $0.691 |
| Feb 20, 2026 | $0.709 |
| 4 days before | -6.31% |
| 4 days after | -5.48% |
| On release day | -1.15% |
| Change in period | -11.44% |
Mar 31, 2026
Missed
| Release date | May 15, 2026 |
| Price on release | $0.700 |
| EPS estimate | -$0.281 |
| EPS actual | -$0.95 |
| EPS surprise | -238.38% |
| Date | Price |
|---|---|
| May 11, 2026 | $0.639 |
| May 12, 2026 | $0.613 |
| May 13, 2026 | $0.650 |
| May 14, 2026 | $0.720 |
| May 15, 2026 | $0.700 |
| May 18, 2026 | $0.527 |
| May 19, 2026 | $0.554 |
| May 20, 2026 | $0.580 |
| May 21, 2026 | $0.673 |
| 4 days before | 9.68% |
| 4 days after | -3.90% |
| On release day | -24.76% |
| Change in period | 5.40% |
Citius Pharmaceuticals Earnings History
Earnings Calendar
FAQ
When is the earnings report for CTXR?
Citius Pharmaceuticals Inc (CTXR) has scheduled its earnings report for Aug 11, 2026 before the markets open.
What is the CTXR price-to-earnings (P/E) ratio?
CTXR P/E ratio as of Jun 22, 2026 (TTM) is -0.265.
What is the CTXR EPS forecast?
The forecasted EPS (Earnings Per Share) for Citius Pharmaceuticals Inc (CTXR) for the first fiscal quarter 2026 is -$0.360.
What are Citius Pharmaceuticals Inc's retained earnings?
On its balance sheet, Citius Pharmaceuticals Inc reported retained earnings of $1.67 million for the latest quarter ending Mar 31, 2026.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
